Literature DB >> 15363987

Effects of rolipram, a phosphodiesterase 4 inhibitor, in combination with imipramine on depressive behavior, CRE-binding activity and BDNF level in learned helplessness rats.

Tetsuji Itoh1, Miwa Tokumura, Kohji Abe.   

Abstract

The brain cAMP regulating system and its downstream elements play a pivotal role in the therapeutic effects of antidepressants. We previously reported the increase in activities of phosphodiesterase 4, a major phosphodiesterase isozyme hydrolyzing cAMP, in the frontal cortex and hippocampus of learned helplessness rats, an animal model for depression. The present study was undertaken to examine the combination of effects of rolipram, a phosphodiesterase 4 inhibitor, with imipramine, a typical tricyclic antidepressant, on depressive behavior in learned helplessness rats. Concurrently, cAMP-response element (CRE)-binding activity and brain-derived neurotrophic factor (BDNF) levels related to the therapeutic effects of antidepressants were determined. Repeated administration of imipramine (1.25-10 mg/kg, i.p.) or rolipram (1.25 mg/kg, i.p.) reduced the number of escape failures in learned helplessness rats. Imipramine could not completely ameliorate the escape behavior to a level similar to that of non-stressed rats even at 10 mg/kg. However, repeated coadministration of rolipram with imipramine (1.25 and 2.5 mg/kg, respectively) almost completely eliminated the escape failures in learned helplessness rats. The reduction of CRE-binding activities and BDNF levels in the frontal cortex or hippocampus in learned helplessness rats were ameliorated by treatment with imipramine or rolipram alone. CRE-binding activities and/or BDNF levels of the frontal cortex and hippocampus were significantly increased by treatment with a combination of rolipram and imipramine compared to those in imipramine-treated rats. These results indicated that coadministration of phosphodiesterase type 4 inhibitors with antidepressants may be more effective for depression therapy and suggest that elevation of the cAMP signal transduction pathway is involved in the antidepressive effects.

Entities:  

Mesh:

Substances:

Year:  2004        PMID: 15363987     DOI: 10.1016/j.ejphar.2004.07.084

Source DB:  PubMed          Journal:  Eur J Pharmacol        ISSN: 0014-2999            Impact factor:   4.432


  24 in total

1.  Alcohol induced depressive-like behavior is associated with a reduction in hippocampal BDNF.

Authors:  Sheketha R Hauser; Bruk Getachew; Robert E Taylor; Yousef Tizabi
Journal:  Pharmacol Biochem Behav       Date:  2011-09-10       Impact factor: 3.533

2.  Dual inhibitors of phosphodiesterase-4 and serotonin reuptake.

Authors:  John R Cashman; Troy Voelker; Han-Ting Zhang; James M O'Donnell
Journal:  J Med Chem       Date:  2009-03-26       Impact factor: 7.446

3.  RNA interference-mediated phosphodiesterase 4D splice variants knock-down in the prefrontal cortex produces antidepressant-like and cognition-enhancing effects.

Authors:  Zhen-Zhen Wang; Yi Zhang; Yan-Qin Liu; Nan Zhao; You-Zhi Zhang; Li Yuan; Lei An; Jing Li; Xiao-Yun Wang; Juan-Juan Qin; Steven P Wilson; James M O'Donnell; Han-Ting Zhang; Yun-Feng Li
Journal:  Br J Pharmacol       Date:  2013-02       Impact factor: 8.739

4.  Effects of estrogen treatment on expression of brain-derived neurotrophic factor and cAMP response element-binding protein expression and phosphorylation in rat amygdaloid and hippocampal structures.

Authors:  Jin Zhou; Huaibo Zhang; Rochelle S Cohen; Subhash C Pandey
Journal:  Neuroendocrinology       Date:  2005-09-21       Impact factor: 4.914

Review 5.  Inhibition of phosphodiesterases as a strategy to achieve neuroprotection in Huntington's disease.

Authors:  Antonella Cardinale; Francesca R Fusco
Journal:  CNS Neurosci Ther       Date:  2018-03-03       Impact factor: 5.243

Review 6.  The role of phosphodiesterases in schizophrenia : therapeutic implications.

Authors:  Judith A Siuciak
Journal:  CNS Drugs       Date:  2008       Impact factor: 5.749

7.  BAG1 plays a critical role in regulating recovery from both manic-like and depression-like behavioral impairments.

Authors:  Sungho Maeng; Joshua G Hunsberger; Brandon Pearson; Peixiong Yuan; Yun Wang; Yanling Wei; Joseph McCammon; Robert J Schloesser; Rulun Zhou; Jing Du; Guang Chen; Bruce McEwen; John C Reed; Husseini K Manji
Journal:  Proc Natl Acad Sci U S A       Date:  2008-06-18       Impact factor: 11.205

8.  Chronic treatment with the selective NOP receptor antagonist [Nphe 1, Arg 14, Lys 15]N/OFQ-NH 2 (UFP-101) reverses the behavioural and biochemical effects of unpredictable chronic mild stress in rats.

Authors:  Giovanni Vitale; Valentina Ruggieri; Monica Filaferro; Claudio Frigeri; Silvia Alboni; Fabio Tascedda; Nicoletta Brunello; Remo Guerrini; Carlo Cifani; Maurizio Massi
Journal:  Psychopharmacology (Berl)       Date:  2009-08-27       Impact factor: 4.530

9.  BDNF level in the rat prefrontal cortex increases following chronic but not acute treatment with duloxetine, a dual acting inhibitor of noradrenaline and serotonin re-uptake.

Authors:  Claudio Mannari; Nicola Origlia; Alessia Scatena; Alessandro Del Debbio; Mario Catena; Grazia Dell'agnello; Alessandra Barraco; Luca Giovannini; Liliana Dell'osso; Luciano Domenici; Armando Piccinni
Journal:  Cell Mol Neurobiol       Date:  2008-01-03       Impact factor: 5.046

Review 10.  Second messenger/signal transduction pathways in major mood disorders: moving from membrane to mechanism of action, part I: major depressive disorder.

Authors:  Mark J Niciu; Dawn F Ionescu; Daniel C Mathews; Erica M Richards; Carlos A Zarate
Journal:  CNS Spectr       Date:  2013-03-05       Impact factor: 3.790

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.